VIB scientist receives major rese...( esearchers succeeded in raising the con...)

Unfortunately, however, scientists ran into difficulties when testing the therapy on larger laboratory animals. After gene therapy, as is also the case with regular injections of coagulation factors, the immune system often recognizes these coagulation factors as foreign and purges them, rendering the treatment ineffective. With the research project that has been selected to receive the award, the VIB research group will seek to identify which mechanisms are involved in the purging of this coagulation factor and how they might develop strategies to prevent this response.

Hemophilia Research Award

With its Hemophilia Research Awards Program, Bayer is supporting research on coagulation disorders in order to develop a better treatment for hemophilia patients. To be awarded such a research grant, the research project must be innovative, of high scientific caliber, and must offer added value to society. Thierry VandenDriessches research project was selected based on an international competition. The VIB researcher will receive 200,000 USD to carry out the project.

Promising research

With this research, the VIB scientists hope to explain the mechanisms that are responsible for causing gene therapy in hemophilia patients to ultimately fail. Knowledge of these mechanisms will play a key role in improving and developing therapeutic treatments.

'"/>

Contact: Evy Vierstraete
info@vib.be
329-244-6611
VIB, Flanders Interuniversity Institute of Biotechnology
9-Jul-2007